The use of sub-anesthetic doses of ketamine to treat major depressive disorder and numerous other psychiatric disorders is on the rise. Unfortunately, many questions remain about the optimal use of ketamine, including route of administration, racemic mixture, role in anti-depressant switching, maintenance therapy, the side effect profile, and illicit use.
The current study added to the body of knowledge and showed that the efficacy of intranasal and intravenous ketamine was similar in patients with major depressive disorder.
The literature was searched for studies involving adults who received intranasal or intravenous ketamine for major depressive disorder. The primary outcome was a response within 24 h of ketamine administration.
Based on 11 studies and 1340 patients with major depressive disorder, there was no difference in efficacy between intranasal and intravenous ketamine.